Special Issue "Novel Anticancer Drug Delivery Systems"
A special issue of Pharmaceutics (ISSN 1999-4923).
Deadline for manuscript submissions: 31 October 2019
Prof. Sanjay Garg
School of Pharmacy and Medical Sciences, University of South Australia, Adelaide South Australia 5000, Australia
Website | E-Mail
Interests: controlled drug delivery; nanoparticles; targeted therapy; anticancer drug delivery systems; nanotechnology; antibacterials for superbugs; wound healing; veterinary formulations
Assoc. Prof. Usha Y. Nayak
Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences (MCOPS), Manipal Academy of Higher Education, Manipal, Karnataka-576104, India
Website | E-Mail
Interests: controlled drug delivery; polymeric nanoparticles; liposomes; nanoemulsions; lipid nanoparticles; chronotherapeutics; solubility enhancement
Cancer is one of the leading causes of death worldwide, and there is a constant rise in cancer cases day by day. According to World Cancer Report, by the year 2020 there may be 15 million new cases of cancer. Currently, the cancer treatment strategies include surgery, chemotherapy, and radiotherapy, and it is widely known that these therapies inhibit the growth also of normal cells and are associated with high toxicity. The area of cancer therapy is a highly dynamic field, and breakthrough advancements are being made to develop novel strategies. Several strategies, such as receptor-based targeting, intracellular drug targeting, stimuli-based drug release, magnetic drug targeting, ultrasound-mediated drug delivery, gene delivery, and cancer stem cell therapy, have added new dimensions to the treatment approaches. These strategies aid in the selective detection and killing of tumour cells with minimal side effects and may be useful to reduce the chances of multidrug resistance, thus improving the quality of life of patients.
This Special Issue of Pharmaceutics focuses on "Novel Anticancer Drug Delivery Systems" which could help solve issues related to side effects, high toxicities, and drug resistance of anticancer drugs. Articles concerning all aspects of novel anticancer drug delivery systems, especially, new materials, strategies, and synthetic approaches are welcome for this Special Issue.
Prof. Dr. Sanjay Garg
Dr. Usha Y. Nayak
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- cancer treatment
- gene therapy
- targeted therapy
- stimuli-based release
- stem cell therapy